

## Synthesis and Absolute Configuration of Chaboside, First Natural Gluco-camptothecin

Norio Aimi,\* Masahiro Ueno, Hiroyuki Hoshino, and Shin-ichiro Sakai


Faculty of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba 263, Japan

**Key words:** Chaboside, Gluco-camptothecin, Total synthesis, Absolute configuration, *Ophiorrhiza* spp., Rubiaceae

**Abstract:** Chaboside, first natural glucosidic camptothecin, was synthesized enantioselectively to clarify the absolute configuration. The corresponding aglycone was also synthesized.

Chaboside (1) was isolated in this laboratory from a Rubiaceous plant, *Ophiorrhiza pumila* Champ.<sup>1)</sup> The structural studies by spectroscopical methods lead us to propose the structure 9-methoxy-10- O-( $\beta$ -D-glucosyloxy)-camptothecin. This compound was the first glycosidic congener of camptothecin and also the first member of camptothecinoids possessing two oxygen functions on the A ring. To confirm the proposed structure and to determine the absolute configuration at the chiral center C-20 enantioselective total synthesis was undertaken.

First, the aglycone of chaboside, 9-methoxy-10-hydroxycamptothecin (2) in racemic form was synthesized. A general synthetic plan which was initially developed by Shanghai research groups<sup>2)</sup> and afterward brushed up by Wall *et al.*<sup>3)</sup> was employed. A-ring part was synthesized as follows. 2,3-Dihydroxy benzaldehyde (3) which was derived from o-vanillin (4) was O-methylated specifically at 2-position by using each one molar equivalent of NaH and MeI to give 5.<sup>4)</sup> Nitration (c-HNO<sub>3</sub>, toluene, -78° ~ -20°C) gave 4-



nitro- (6) and 6-nitro (7) derivatives with the same yields of 36%. The fact that the latter isomer (7) was the objective 6-nitro derivative was proved through its conversion to 2,3-dimethoxy-6-nitrobenzaldehyde ethyleneketal (8), which was prepared from o-vanillin through a different sequence of reactions.<sup>5)</sup> 4-O-Benzyl ether (9) was converted to 10, which was subsequently reduced ( $\text{Na}_2\text{S}$ , EtOH,  $\Delta$ ) to 11. Condensation of 11 with tricyclic ketone (12)<sup>3)</sup> ( $\text{TsOH}$ , toluene,  $\Delta$ , Y. 32%) followed by oxidation ( $\text{CuCl}_2$ ,  $\text{O}_2$ , DMF,  $\text{H}_2\text{O}$ ,  $\text{Me}_2\text{NH}$ ,  $\Delta$ ) of the resultant quinoline (13) afforded 14 (40%). Removal of the protective group from 14 gave the expected (*dl*)-9-methoxy-10-hydroxycamptothecin.<sup>6)</sup> This compound was identified in all respects excepting optical property with chaboside aglycone (2) which was obtained from 1 through hydrolysis with dilute sulfuric acid.

Then with the purpose of determining the absolute configuration of chaboside (1) synthesis in an enantioselective manner was carried out. The A-ring component (16) with O- $\beta$ -D-glucosyl group at the proper position was prepared through glycosidation of the above nitrobenzaldehyde (7) with acetobromoglucose. Catalytic reduction of the resultant 15 in the presence of  $\text{PtO}_2$  gave the corresponding anthranil aldehyde (16), which was then deacetylated to 17. Recently Tagawa *et al.*, Daiichi Pharmaceutical Industry, reported chiral induction by use of D-proline leading to synthesis of chiral tricyclic component (18) corresponding to CDE ring.<sup>7)</sup> The same compound was synthesized and was condensed with the above A-ring component (17) ( $\text{AcOH}$ ,  $\text{MeOH}$ ,  $\Delta$ , Y. 45%). The resultant material (1) was shown to be identical with the natural chaboside in all respects including CD spectrum. Thus the absolute configuration at C-20 of chaboside was proved to be *S*, the same configuration as camptothecin.

ACKNOWLEDGMENTS; This work was supported financially by a Grant-in-Aids for Scientific Researches (No. 02670942) from the Ministry of Education, Science, and Culture of Japan.

#### REFERENCES

- 1) N. Aimi, H. Hoshino, M. Nishimura, S. Sakai, and J. Haginiwa, *Tetrahedron Lett.*, **31**, 5169 (1990)
- 2) Shanghai No. 5 Pharmaceutical Plant, Shanghai No. 12 Pharmaceutical Plant, Shanghai Institute of Pharmaceutical Industrial Research, and Shanghai Institute of Materia Medica, *Scientia Sinica*, **21**, 87 (1978)
- 3) M. C. Wani, P. E. Ronman, J. T. Lindley, and M. E. Wall, *J. Med. Chem.*, **23**, 554 (1980)
- 4) S. V. Kessar, Y. P. Gupta, T. Mohammad, M. Goyal, and K. K. Sawal, *J. Chem. Soc., Chem. Commun.*, **1983**, 400
- 5) W. Reid and H. Schiller, *Chem. Ber.*, **85**, 216 (1952)
- 6) Amorphous pale yellow powder. UV  $\lambda_{\text{max}}$  (EtOH) nm; 223, 271, 295, 330, and 386.  $^1\text{H-NMR}$  (500MHz)  $\delta$  ( $\text{DMSO-d}_6$ ); 0.88 (3H, t,  $J=7.4$  Hz, 18- $\text{H}_3$ ), 1.84 (1H, q,  $J=6.8$  Hz, H-19), 1.89 (1H, q,  $J=7.1$  Hz, H-19), 3.94 (3H, s, O- $\text{CH}_3$ ), 5.26 (2H, s, 5- $\text{H}_2$ ), 5.39 (1H, d,  $J=16.0$  Hz, H-17), 5.43 (1H, d,  $J=16.0$  Hz, H-17), 6.50 (1H, s, 20-OH), 7.27 (1H, s, H-14), 7.54 (1H, d,  $J=9.1$  Hz, H-11), 7.84 (1H, d,  $J=9.1$  Hz, H-12), 8.66 (1H, s, H-7), and 10.18 (1H, s, 10-OH).
- 7) A. Ejima, H. Terasawa, M. Sugimori, and H. Tagawa, *Tetrahedron Lett.*, **30**, 2639 (1989); *J. Chem. Soc., Perkin I*, **1990**, 27

(Received in Japan 6 May 1992)